866-997-4948(US-Canada Toll Free)

Progressive Relapsing Multiple Sclerosis (PRMS) - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Dec 2016

Category :

Pharmaceutical

No. of Pages : 35 Pages

Progressive Relapsing Multiple Sclerosis (PRMS) - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Progressive Relapsing Multiple Sclerosis Pipeline Review, H2 2016, provides an overview of the Progressive Relapsing Multiple Sclerosis (Central Nervous System) pipeline landscape.

Progressive-relapsing multiple sclerosis (PRMS) refers to a pattern of relapses within primary-progressive MS (PPMS). Signs of PRMS include muscle spasms, weak muscles, dizziness, chronic pain and vision changes. Risk factors include age, family history, autoimmune diseases and smoking. Treatment includes immunosuppressant drugs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Progressive Relapsing Multiple Sclerosis Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Progressive Relapsing Multiple Sclerosis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Progressive Relapsing Multiple Sclerosis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Progressive Relapsing Multiple Sclerosis (PRMS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I and Preclinical stages are 2 and 3 respectively.

Progressive Relapsing Multiple Sclerosis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Progressive Relapsing Multiple Sclerosis (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Progressive Relapsing Multiple Sclerosis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Progressive Relapsing Multiple Sclerosis (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Progressive Relapsing Multiple Sclerosis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Progressive Relapsing Multiple Sclerosis (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Progressive Relapsing Multiple Sclerosis (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Progressive Relapsing Multiple Sclerosis (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Progressive Relapsing Multiple Sclerosis (PRMS) Overview 6
Therapeutics Development 7
Pipeline Products for Progressive Relapsing Multiple Sclerosis (PRMS) - Overview 7
Progressive Relapsing Multiple Sclerosis (PRMS) - Therapeutics under Development by Companies 8
Progressive Relapsing Multiple Sclerosis (PRMS) - Pipeline Products Glance 9
Clinical Stage Products 9
Early Stage Products 10
Progressive Relapsing Multiple Sclerosis (PRMS) - Products under Development by Companies 11
Progressive Relapsing Multiple Sclerosis (PRMS) - Companies Involved in Therapeutics Development 12
Cognosci Inc 12
Genzyme Corp 13
MedImmune LLC 14
VivaCell Biotechnology Espana SL 15
Progressive Relapsing Multiple Sclerosis (PRMS) - Therapeutics Assessment 16
Assessment by Monotherapy Products 16
Assessment by Target 17
Assessment by Mechanism of Action 19
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Drug Profiles 25
COG-112 - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
COG-133 - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
GZ-402668 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
inebilizumab - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
VCE-0032 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
Progressive Relapsing Multiple Sclerosis (PRMS) - Dormant Projects 32
Progressive Relapsing Multiple Sclerosis (PRMS) - Discontinued Products 33
Appendix 34
Methodology 34
Coverage 34
Secondary Research 34
Primary Research 34
Expert Panel Validation 34
Contact Us 34
Disclaimer 35

List of Tables
Number of Products under Development for Progressive Relapsing Multiple Sclerosis (PRMS), H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Clinical Stage Development, H2 2016 9
Comparative Analysis by Early Stage Development, H2 2016 10
Products under Development by Companies, H2 2016 11
Progressive Relapsing Multiple Sclerosis (PRMS) - Pipeline by Cognosci Inc, H2 2016 12
Progressive Relapsing Multiple Sclerosis (PRMS) - Pipeline by Genzyme Corp, H2 2016 13
Progressive Relapsing Multiple Sclerosis (PRMS) - Pipeline by MedImmune LLC, H2 2016 14
Progressive Relapsing Multiple Sclerosis (PRMS) - Pipeline by VivaCell Biotechnology Espana SL, H2 2016 15
Assessment by Monotherapy Products, H2 2016 16
Number of Products by Stage and Target, H2 2016 18
Number of Products by Stage and Mechanism of Action, H2 2016 20
Number of Products by Stage and Route of Administration, H2 2016 22
Number of Products by Stage and Molecule Type, H2 2016 24
Progressive Relapsing Multiple Sclerosis (PRMS) - Dormant Projects, H2 2016 32
Progressive Relapsing Multiple Sclerosis (PRMS) - Discontinued Products, H2 2016 33

List of Figures
Number of Products under Development for Progressive Relapsing Multiple Sclerosis (PRMS), H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Assessment by Monotherapy Products, H2 2016 16
Number of Products by Targets, H2 2016 17
Number of Products by Stage and Targets, H2 2016 17
Number of Products by Mechanism of Actions, H2 2016 19
Number of Products by Stage and Mechanism of Actions, H2 2016 19
Number of Products by Routes of Administration, H2 2016 21
Number of Products by Stage and Routes of Administration, H2 2016 21
Number of Products by Molecule Types, H2 2016 23
Number of Products by Stage and Molecule Types, H2 2016 23

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *